Novavax (NVAX) Competitors $8.66 -0.11 (-1.25%) (As of 12:21 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NVAX vs. ALKS, FOLD, GERN, LGND, MNKD, CLDX, DVAX, BCRX, MYGN, and INVAShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Myriad Genetics (MYGN), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Novavax vs. Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals MannKind Celldex Therapeutics Dynavax Technologies BioCryst Pharmaceuticals Myriad Genetics Innoviva Novavax (NASDAQ:NVAX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability. Do analysts prefer NVAX or ALKS? Novavax currently has a consensus target price of $17.83, indicating a potential upside of 103.34%. Alkermes has a consensus target price of $35.42, indicating a potential upside of 20.59%. Given Novavax's higher probable upside, equities research analysts plainly believe Novavax is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Alkermes 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58 Does the media refer more to NVAX or ALKS? In the previous week, Alkermes had 9 more articles in the media than Novavax. MarketBeat recorded 14 mentions for Alkermes and 5 mentions for Novavax. Alkermes' average media sentiment score of 1.21 beat Novavax's score of 0.57 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NVAX or ALKS more profitable? Alkermes has a net margin of 22.15% compared to Novavax's net margin of -32.18%. Alkermes' return on equity of 24.92% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Novavax-32.18% N/A -17.05% Alkermes 22.15%24.92%14.55% Which has more risk & volatility, NVAX or ALKS? Novavax has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Does the MarketBeat Community prefer NVAX or ALKS? Novavax received 151 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 74.08% of users gave Novavax an outperform vote while only 70.51% of users gave Alkermes an outperform vote. CompanyUnderperformOutperformNovavaxOutperform Votes84974.08% Underperform Votes29725.92% AlkermesOutperform Votes69870.51% Underperform Votes29229.49% Which has stronger earnings & valuation, NVAX or ALKS? Alkermes has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$983.71M1.43-$545.06M-$2.26-3.88Alkermes$1.51B3.16$355.76M$1.9515.06 Do insiders & institutionals have more ownership in NVAX or ALKS? 53.0% of Novavax shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 4.9% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAlkermes beats Novavax on 14 of the 18 factors compared between the two stocks. Ad WealthPressIs the Trump/Musk duo good for shares of TSLA?If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$3.05B$5.37B$8.94BDividend YieldN/A1.84%5.33%4.05%P/E Ratio-3.8847.13117.7718.01Price / Sales1.43489.601,425.09155.72Price / CashN/A175.8442.8638.60Price / Book-2.674.967.356.66Net Income-$545.06M-$41.68M$118.53M$224.93M7 Day Performance0.23%10.83%3.40%2.50%1 Month Performance-6.20%11.26%2.50%10.23%1 Year Performance57.45%38.03%36.24%30.14% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax3.6737 of 5 stars$8.66-1.3%$17.83+105.9%+57.5%$1.39B$847.25M-3.831,543ALKSAlkermes4.4377 of 5 stars$29.20+0.6%$35.42+21.3%+20.9%$4.72B$1.66B14.882,100Positive NewsFOLDAmicus Therapeutics4.4409 of 5 stars$10.05+0.7%$17.63+75.4%-11.2%$3.00B$399.36M-29.38480Analyst DowngradeShort Interest ↑Positive NewsGERNGeron4.0628 of 5 stars$4.03-2.2%$7.05+74.9%+103.0%$2.44B$240,000.00-12.88141Options VolumePositive NewsLGNDLigand Pharmaceuticals4.9691 of 5 stars$122.92+1.2%$144.83+17.8%+108.9%$2.32B$131.31M48.5780Insider TradePositive NewsMNKDMannKind3.3732 of 5 stars$6.59-2.8%$8.67+31.5%+74.8%$1.82B$198.96M97.43400CLDXCelldex Therapeutics3.4489 of 5 stars$27.29-0.5%$62.25+128.1%-15.0%$1.81B$9.98M-10.68160Positive NewsDVAXDynavax Technologies4.5606 of 5 stars$12.83-0.2%$22.00+71.5%-5.4%$1.69B$232.28M98.93408Short Interest ↑BCRXBioCryst Pharmaceuticals4.3756 of 5 stars$7.34-2.1%$15.60+112.5%+20.0%$1.52B$331.41M-12.29530Short Interest ↓Positive NewsMYGNMyriad Genetics4.356 of 5 stars$16.48+1.3%$27.36+66.0%-13.2%$1.50B$753.20M-12.522,700Short Interest ↓INVAInnoviva1.5828 of 5 stars$19.17+0.9%N/A+36.7%$1.20B$352.75M27.52112Positive News Related Companies and Tools Related Companies Alkermes Alternatives Amicus Therapeutics Alternatives Geron Alternatives Ligand Pharmaceuticals Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives BioCryst Pharmaceuticals Alternatives Myriad Genetics Alternatives Innoviva Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVAX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
